On 18 May 2018 WHO issued a statement on potential safety issue affecting women living with HIV using dolutegravir at the time of conception. Since then WHO headquarters, regional and country offices have been actively working with countries and partners, including civil society, to explore policy and implementation implications and actions to help ensure that any potential risk is appropriately considered and managed while also ensuring minimum impact on national treatment programmes.
Wednesday, 6 June 2018, 1500-1600hrs CET
Moderation: Andy Seale
– Introduction – Gottfried Hirnschall, Director HIV Department, WHO
– Presentation on study findings, implications and actions taken to date – Meg Doherty, Coordinator, HIV/TAC, WHO
– Discussion on civil society reactions and concerns – Florence Anam, Advocacy and Communication Manager, ICW and Coco Jervis, Senior Communications and Advocacy Officer, GNP+
To join the webinar, click here.